CBAY
Cymabay Therapeutics
CBAY
CBAY
Delisted
CBAY was delisted on the 21st of March, 2024.
200 hedge funds and large institutions have $2.73B invested in Cymabay Therapeutics in 2023 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 79 increasing their positions, 60 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
200
Holders Change
+11
Holders Change %
+5.82%
% of All Funds
2.93%
Holding in Top 10
10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-16.67%
% of All Funds
0.15%
New
46
Increased
79
Reduced
60
Closed
33
Calls
$84.7M
Puts
$20.6M
Net Calls
+$64.2M
Net Calls Change
+$62M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
$105M |
| 2 |
BlackRock
New York
|
$227M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
$72.3M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
$33.3M |
| 5 |
Morgan Stanley
New York
|
$45.2M |
